KLA Corp. vs Medpace Holdings Inc — how do they compare? KLA Corp. trades at $208.25 (market cap $261.92B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: KLA Corp. is far larger — about 15.5× Medpace Holdings Inc's market cap, and KLA Corp. pays a 0.46% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| KLAC | MEDP | |
|---|---|---|
Market Cap | $261.92B | $16.90B |
Sector | Technology | Technology |
52-Week High | $301.71 | $620.59 |
52-Week Low | $84.39 | $393.42 |
Enterprise Value | $263.17B | $16.52B |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $208.27, up 8.06% on the day, reflecting strong momentum amid the AI-driven semiconductor equipment rally. The stock exhibits bullish technical signals with recent earnings beats and robust profitability, including a 35.57% net income margin. Recent corporate actions include a 1:10 stock split and dividend declarations, while analyst consensus leans heavily bullish with a $246.93 price target.
Outlook remains positive given KLAC's exposure to advanced packaging growth and AI chip demand, though elevated valuation ratios (P/E of 54.77) and technical overbought conditions near resistance at $209 pose near-term risks. Long-term investors may find value in its fundamental strength, but volatility from sector cyclicality warrants caution.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →